NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable or Borderline Resectable Pancreatic Cancer
Conditions: Borderline Resectable Pancreatic Carcinoma; Resectable Pancreatic Ductal Adenocarcinoma; Stage 0 Pancreatic Cancer AJCC v8; Stage I Pancreatic Cancer AJCC v8; Stage IA Pancreatic Cancer AJCC v8; Stage IB Pancreatic Cancer AJCC v8 Interventions: Drug: Capecitabine; Drug: Fluorouracil; Drug: Irinotecan Hydrochloride; Drug: Leucovorin Calcium; Drug: Losartan Potassium; Drug: Oxaliplatin; Radiation: Radiation Therapy; Procedure: Resection Sponsors: OHSU Knight Cancer Institute; Oregon Health and Science University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Adenocarcinoma | Calcium | Cancer | Cancer & Oncology | Carcinoma | Eloxatin | Pancreas | Pancreatic Cancer | Potassium | Research | Xeloda